BOXED WARNING High potential for abuse, misuse, and addiction; misuse/abuse of CNS stimulants can result in overdose and death. Assess abuse risk before prescribing and monitor throughout treatment.
FDA dosing
Population
Start
Target
Max
Attention Deficit Hyperactivity Disorder (ADHD)
Patients 6 years and older
2.5 or 5 mg QD in the morning
Titrate to clinical response
20 mg QD
Titration Increase in increments of 2.5 to 10 mg/day every 4 to 7 days
Renal Undefined
Hepatic Undefined
Instructions
Administer orally once daily in the morning, with or without food
Extended-release oral suspension: shake bottle well before each dose; use the provided oral dosing dispenser
Extended-release tablets: may be chewed or swallowed whole (5 mg tablet is scored, divisible to 2.5 mg)
Oral suspension and tablets are substitutable on a mg-per-mg basis; do not substitute mg-per-mg for other amphetamine products
Assess for cardiac disease and screen for tics/Tourette's before initiating